| RESEARCH ARTICLE
|Year : 2011 | Volume
| Issue : 4 | Page : 437-440
Comparison of nebivolol and atenolol on blood pressure, blood sugar, and lipid profile in patients of essential hypertension
VA Badar1, Sachin K Hiware1, Meena P Shrivastava1, VR Thawani2, MM Hardas3
1 Department of Pharmacology, Indira Gandhi Government Medical College, Nagpur, India
2 Department of Pharmacology, Government Medical College, Nagpur, Maharashtra, India
3 Department of Medicine, Indira Gandhi Government Medical College, Nagpur, India
Background: Nebivolol is a third-generation β-blocker, with highest β1 selectivity and nitric-oxide-derived vasodilatation. It also exhibits antiproliferative and antioxidant property that has beneficial metabolic profile compared to second-generation β blockers like atenolol. This study was planned to study the comparative effects of nebivolol and atenolol on metabolic parameters in patients with essential hypertension.
Materials and Methods: A prospective, randomized, parallel, open-label clinical study was carried out on patients with essential hypertension. The patients were randomly assigned to receive tablet atenolol (Group A) and nebivolol (Group B) for a period of 24 weeks. Investigations were carried out at baseline and at the end of study period, that is, 24 weeks. Out of 69 patients, 60 completed the study and the data was analyzed using student's t-test. P < 0.05 was considered statistically significant.
Results: Atenolol and nebivolol both showed significant (P < 0.001) antihypertensive action after 24 weeks. Mean blood sugar and lipid profile were found to be significantly (P < 0.001) elevated after 24 weeks of treatment with atenolol but not with nebivolol. Heart rate was significantly (P < 0.001) decreased in both groups at 24 weeks.
Conclusion: In view of metabolic adverse effects of atenolol, nebivolol is the better choice whenever β-blockers have to be used in essential hypertension.
V A Badar
Department of Pharmacology, Indira Gandhi Government Medical College, Nagpur
Source of Support: None, Conflict of Interest: None
[FULL TEXT] [PDF]*